Efficacy and Safety of Lobeglitazone Monotherapy in Patients with Type 2 Diabetes Mellitus over 24-Weeks: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Trial

OBJECTIVE: The aim of this study was to assess the glucose-lowering and lipid-modifying effects, and safety profile of lobeglitazone, a novel peroxisome proliferator-activated receptor- γ agonist, compared to placebo as a monotherapy in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: In...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Sin Gon, Kim, Doo Man, Woo, Jeong-Taek, Jang, Hak Chul, Chung, Choon Hee, Ko, Kyung Soo, Park, Jeong Hyun, Park, Yong Soo, Kim, Sang Jin, Choi, Dong Seop
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3988010/
https://www.ncbi.nlm.nih.gov/pubmed/24736628
http://dx.doi.org/10.1371/journal.pone.0092843

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3988010/
https://www.ncbi.nlm.nih.gov/pubmed/24736628
http://dx.doi.org/10.1371/journal.pone.0092843

Ejemplares similares